Virtual Library
Start Your Search
Dilek Erdem
Author of
-
+
EP1.01 - Advanced NSCLC (ID 150)
- Event: WCLC 2019
- Type: E-Poster Viewing in the Exhibit Hall
- Track: Advanced NSCLC
- Presentations: 1
- Now Available
- Moderators:
- Coordinates: 9/08/2019, 08:00 - 18:00, Exhibit Hall
-
+
EP1.01-104 - Denosumab Experience in Lung Cancer Patients with Bone Metastases (Now Available) (ID 1005)
08:00 - 18:00 | Presenting Author(s): Dilek Erdem
- Abstract
Background
Denosumab, is a monoclonal antibody against receptor activator nuclear factor kappa B ligand (RANKL). It inhibits the bone resorbtion and therefore decreases skeletal related events (SRE). It is practically used instead of zoledronic acid in the tumors with bone metastasis. This study aims to reveal general characteristics and adverse event profile of lung cancer patients with bone metastasis.
Method
This study includes 17 patients referred to outpatient clinic who have lung cancer with bone metastasis between July 2014 and July 2018. We retrospectively analyzed the data. The patients who were on denosumab treatment at least 2 months were included.
Result
All of the patients were men (n=17). The median age was 66,8 years old (range 34-84 years). All of the patients had non small cell lung cancer histology. Six patients (35,2 %) had squamous cell carcinoma and eleven patients were with adenocarcinoma histology. Except for two patients, all had metastatic disease. 3 had bone metastasis after the cancer diagnosis while others had bone metastasis initially. Seven patients had another metastatic sites besides bone metastasis and the most common metastatic site was lung (57,1 %). Among eleven adenocarcinoma patients, 4 had EGFR mutation (36 %): 2 with exon 19 deletion and 2 with exon 21 mutation. These 4 patients had anti-EGFR treatment. The patients had denosumab in the range of 2-33 months, with the median 6,5 months. 10 patients had radiation therapy besides denosumab treatment. Six patients (35,2 %) were switched from zoledronic acid therapy to denosumab because of renal failure. There was no hypocalcemic status because all the patients had laboratory checks for calcium, vitamin D and albümin and treated according to the deficiency before denosumab therapy. Also during denosumab treatment we did not see any osteonecrosis because all had undergone dentist examination before the initiation of the drug. 29,4 % (five patients) died during the therapy. All of the patients passed on because of the disease progression.
Conclusion
Bone is the most common metastatic site of lung cancer. Bone metastasis cause morbidities like pain, fracture, hypercalcemia and spinal cord compression. In our study, unlike the literatüre, there were no hypocalcemia or osteonecrosis. This outcome may be connected not only the shortness of the follow-up but also the initial replacement of calcium and vitamin D. Because of being effective and with less toxicity, denosumab may be a positive option in lung cancer patients with bone metastasis.
